Suppr超能文献

戈谢氏病骨骼受累:阿根廷戈谢氏病患者预后因素的观察性多中心研究。

Skeletal involvement in Gaucher disease: An observational multicenter study of prognostic factors in the Argentine Gaucher disease patients.

机构信息

Hospital de Niños "Ricardo Gutiérrez", CABA.

Hospital C. Milstein, CABA.

出版信息

Am J Hematol. 2016 Oct;91(10):E448-53. doi: 10.1002/ajh.24486. Epub 2016 Aug 22.

Abstract

Patients with Gaucher type 1 (GD1) throughout Argentina were enrolled in the Argentine bone project to evaluate bone disease and its determinants. We focused on presence and predictors of bone lesions (BL) and their relationship to therapeutic goals (TG) with timing and dose of enzyme replacement therapy (ERT). A total of 124 patients on ERT were enrolled in a multi-center study. All six TG were achieved by 82% of patients: 70.1% for bone pain and 91.1% for bone crisis. However, despite the fact that bone TGs were achieved, residual bone disease was present in 108 patients on ERT (87%) at time 0. 16% of patients showed new irreversible BL (bone infarcts and avascular osteonecrosis) despite ERT, suggesting that they appeared during ERT or were not detected at the moment of diagnosis. We observed 5 prognostic factors that predicted a higher probability of being free of bone disease: optimal ERT compliance; early diagnosis; timely initiation of therapy; ERT initiation dose ≥45 UI/kg/EOW; and the absence of history of splenectomy. Skeletal involvement was classified into 4 major phenotypic groups according to BL: group 1 (12.9%) without BL; group 2 (28.2%) with reversible BL; group 3 (41.9%) with reversible BL and irreversible chronic BL; and group 4 (16.9%) with acute irreversible BL. Our study identifies prognostic factors for achieving best therapeutic outcomes, introduces new risk stratification for patients and suggests the need for a redefinition of bone TG. Am. J. Hematol. 91:E448-E453, 2016. © 2016 Wiley Periodicals, Inc.

摘要

阿根廷各地的戈谢病 1 型(GD1)患者参加了阿根廷骨骼项目,以评估骨骼疾病及其决定因素。我们专注于骨骼病变(BL)的存在和预测因素及其与治疗目标(TG)的关系,包括酶替代疗法(ERT)的时间和剂量。共有 124 名接受 ERT 的患者参加了这项多中心研究。所有六个 TG 都被 82%的患者实现:70.1%用于骨痛,91.1%用于骨危机。然而,尽管达到了骨骼 TG,但在开始 ERT 时仍有 108 名患者(87%)存在残留骨骼疾病。尽管接受了 ERT,但仍有 16%的患者出现新的不可逆 BL(骨梗死和缺血性骨坏死),这表明它们出现在 ERT 期间或在诊断时未被发现。我们观察到 5 个预测因素,它们预测骨骼疾病无进展的可能性更高:ERT 依从性最佳;早期诊断;及时开始治疗;ERT 起始剂量≥45 UI/kg/每周;无脾切除术史。根据 BL 将骨骼受累分为 4 个主要表型组:组 1(12.9%)无 BL;组 2(28.2%)有可逆性 BL;组 3(41.9%)有可逆性 BL 和不可逆性慢性 BL;组 4(16.9%)有急性不可逆性 BL。我们的研究确定了实现最佳治疗效果的预测因素,为患者引入了新的风险分层,并表明需要重新定义骨骼 TG。Am. J. Hematol. 91:E448-E453, 2016. © 2016 Wiley Periodicals, Inc.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验